-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yesterday, the US FDA announced that it granted emergency use authorization (EUA) for the monoclonal antibody therapy sotrovimab jointly developed by Vir Biotechnology and GlaxoSmithKline (GSK) for the treatment of adults and pediatric patients with mild to moderate COVID-19.
Yesterday, the US FDA announced that it granted emergency use authorization (EUA) for the monoclonal antibody therapy sotrovimab jointly developed by Vir Biotechnology and GlaxoSmithKline (GSK) for the treatment of adults and pediatric patients with mild to moderate COVID-19.
"It's not difficult to find antibodies, but it's difficult to find the ideal antibody"
"It's not difficult to find antibodies, but it's difficult to find the ideal antibody"Let us turn the clock back to the beginning of 2020.
However, there are many types of neutralizing antibodies produced in the human body.
Scientists from the University of Washington and Vir Biotechnology in the United States have analyzed the memory B cells of a recovered patient who was infected with SARS-CoV-1 in 2003 and found a model called S309.
Cooperation can be a win-win situation
However, it is found that S309 is only the starting point for the development of neutralizing antibody therapy.
In February 2020, Dr.
Vir has also reached cooperation agreements with other companies such as WuXi Biologics and Biogen to accelerate the production of antibody therapies in different development stages, allowing candidate antibody therapies to enter the clinical development stage in the shortest possible time.
Source: WuXi AppTec's content team drawing
In April 2020, GlaxoSmithKline and Vir reached a research and development cooperation to further accelerate the development of candidate new crown neutralizing antibodies.
In March of this year, sotrovimab’s phase 3 clinical trial received good news.
The bright future of antibody therapy against infectious diseases
In the battle against COVID-19, the rapid development of the new crown vaccine has attracted widespread attention.
Compared with vaccines, neutralizing antibodies can provide people with immediate resistance to the virus strains that are circulating, and for those who cannot respond effectively to the vaccine due to physical reasons (including the elderly and patients with weakened immune systems).
Take Vir's sotrovimab as an example.
The hepatitis B antibody therapy VIR-3434, which also uses this technology, also obtained very positive initial results in early clinical trials for the treatment of hepatitis B earlier this year.
Related reading: Interview with Dr.
In February of this year, GlaxoSmithKline and Vir further expanded their research and development cooperation, and will use Vir’s antibody technology platform to develop innovative therapies for the treatment of influenza and other respiratory viruses.
In an in-depth review published a few days ago in the journal Cell, the author stated that in the use of monoclonal antibodies to treat infectious diseases, the accumulated clinical experience of antibody therapy in the past year has exceeded the sum of the previous 20 years.
We hope that the valuable experience accumulated due to the new crown epidemic can open up a broad future for antibody therapy to treat and prevent infectious diseases.
